Nice | Omalizumab for chronic urticaria

20th July 2015 by Louise Hudman

Nice | Omalizumab for chronic urticaria

This is a new guideline from Nice recommending that omalizumab can be considered in chronic urticaria.

Apparently it is already being used on occasion, though due to cost, it is more common for immunosuppressants like ciclosporin to be used. Omalizumab is preferred because of less need for monitoring.

It is not disease modifying and repeat courses are likely to be required.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"LocumDeck does everything you want it to do in an instant and with audit trails.

I absolutely love the facility for receiving Locum's invoices and the facility for signing the Pension Forms electronically and they are then instantly sent with an audit trail! It is fabulous!

You are notified the moment a Locum GP adds availability which is just fantastic, I spend a lot of time just chasing agencies to see if they have availability, so to be notified the moment availability is advertised is a new concept and very welcome! I have no hesitation in recommending LocumDeck - it has already eased my workload!"

Sue, Practice Manager in Portsmouth

See the full list of features within our NASGP membership plans

Membership